NMAD: the balance sheet

MyFinsight

Balance Sheets	2026-06-30
Cash	12,670,143
Prepaid insurance	56,388
Other prepaid expenses	72,488
Note receivable nomad transportable power systems	6,500,000
Total current assets	19,299,019
Light proton therapy system equipment	6,607,419
Operating lease right-of-use assets	742,427
Total assets	26,648,865

Related parties accounts payable and accrued expenses	327,890
Research and development contract liabilities	231,342
Operating lease liabilities, current	940,775
Total current liabilities	1,500,007
Operating lease liabilities, long-term	161,019
Total liabilities	1,661,026
Common stock, 0.0001 par value authorized 100,000,000 shares issued and outstanding 15,417,444 and 8,790,102 shares at june 30, 2026 and december 31, 2025, respectively	1,541
Additional paid-in capital	86,097,966
Accumulated deficit	-62,188,147
Total lixte biotechnology stockholders equity	23,911,360
Non-controlling interest	1,076,479
Total stockholders equity	24,987,839
Total liabilities and stockholders equity	26,648,865

Unit: Dollar. Numbers labeled with * are estimated quarterly values.